A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

被引：51
|
作者：
Kelleher, AD [1 ]
Puls, RL
Bebbington, M
Boyle, D
Ffrench, R
Kent, SJ
Kippax, S
Purcell, DFJ
Thomson, S
Wand, H
Cooper, DA
Emery, S
机构：
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[2] St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia
[3] St Vincents Hosp, Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia
[4] Australian Federat AIDS Org, Newtown, NSW, Australia
[5] CSIRO, Div Livestock Ind, Australian Anim Hlth Lab, Geelong, Vic, Australia
[6] Sydney Childrens Hosp, Westfield Labs, Randwick, NSW, Australia
[7] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia
[8] Univ New S Wales, Natl Ctr HIV Social Res, Sydney, NSW, Australia
[9] Australian Natl Univ, John Curtin Sch Med, Div Cell Biol & Immunol, Canberra, ACT, Australia
来源：
AIDS | 2006年 / 20卷 / 02期
关键词：
D O I：
10.1097/01.aids.0000199819.40079.e9
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 X 10(7) \pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
引用
收藏
页码：294 / 297
页数：4
相关论文
共 50 条
  • [1] An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase 1/11a trial in Thai volunteers at low risk of HIV infection
    Hemachandra, Atchriya
    Puls, Rebekah L.
    Sirivichayakul, Sunee
    Kerr, Stephen
    Thantiworasit, Pattarawat
    Ubolyam, Sasiwimol
    Cooper, David A.
    Emery, Sean
    Phanuphak, Praphan
    Kelleher, Anthony
    Ruxrungtham, Kiat
    HUMAN VACCINES, 2010, 6 (10): : 835 - 840
  • [2] Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    Flynn, MN
    Forthal, DN
    Harro, CD
    Judson, FN
    Mayer, KH
    Para, MF
    Gilbert, PB
    Hudgens, MG
    Metch, BJ
    Self, SG
    Berman, PW
    Francis, DP
    Gurwith, M
    Heyward, WL
    Jobes, DV
    Peterson, ML
    Popovic, V
    Sinangil, FM
    Gurwith, M
    Jobes, DV
    Peterson, ML
    Sinangil, FM
    Berman, PW
    Francis, DP
    Heyward, WL
    Gilbert, PB
    Hudgens, MG
    Metch, BJ
    Self, SG
    Adamczyk, A
    Baker, RL
    Brand, D
    Brown, SJ
    Buchbinder, S
    Buggy, BP
    Cade, J
    Caldwell, MC
    Celum, C
    Creticos, C
    Coutinho, RA
    Lindenburg, K
    Daly, P
    DeJesus, E
    Di-Carlo, R
    Fenstersheib, M
    Flynn, N
    Forthal, D
    Gripshover, B
    Gorse, GJ
    Belshe, R
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05): : 654 - 665
  • [3] Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
    Buchbinder, Susan P.
    Grunenberg, Nicole A.
    Sanchez, Brittany J.
    Seaton, Kelly E.
    Ferrari, Guido
    Moody, M. Anthony
    Frahm, Nicole
    Montefiori, David C.
    Hay, Christine M.
    Goepfert, Paul A.
    Baden, Lindsey R.
    Robinson, Harriet L.
    Yu, Xuesong
    Gilbert, Peter B.
    McElrath, M. Juliana
    Huang, Yunda
    Tomaras, Georgia D.
    PLOS ONE, 2017, 12 (07):
  • [4] Randomized, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-γ in HIV-1 Infected Subjects
    Emery, S.
    Workman, C.
    Puls, R. L.
    Bloch, M.
    Baker, D.
    Bodsworth, N.
    Anderson, J.
    Crowe, S. M.
    French, M. A. H.
    Hoy, J.
    Aichelburg, A.
    Ward, L. D.
    Boyle, D. B.
    Law, M. G.
    Kelleher, A. D.
    Cooper, D. A.
    HUMAN VACCINES, 2005, 1 (06): : 232 - 238
  • [5] HIV-1 INHIBITION BY AZIDOTHYMIDINE IN A CONCURRENTLY RANDOMIZED PLACEBO-CONTROLLED TRIAL
    PARKS, WP
    PARKS, ES
    FISCHL, MA
    LEUTHER, MD
    ALLAIN, JP
    NUSINOFFLEHRMAN, S
    BARRY, DW
    MAKUCH, RW
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1988, 1 (02): : 125 - 130
  • [6] Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Trial in India
    Mehendale, S. M.
    Thakar, M.
    M, M.
    Sahay, S.
    P, S.
    Verma, A.
    Kurle, S.
    Shete, A.
    Kochhar, S.
    Gilmour, J.
    Goyal, R.
    Dally, L.
    Cox, J. H.
    Excler, J.
    Fast, P.
    V, K.
    Paranjape, R.
    Vd, R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A125 - A126
  • [7] A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy
    McMahon, Deborah K.
    Zheng, Lu
    Cyktor, Joshua C.
    Aga, Evgenia
    Macatangay, Bernard J.
    Godfrey, Catherine
    Para, Michael
    Mitsuyasu, Ronald T.
    Hesselgesser, Joseph
    Dragavon, Joan
    Dobrowolski, Curtis
    Karn, Jonathan
    Acosta, Edward P.
    Gandhi, Rajesh T.
    Mellors, John W.
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (04): : 648 - 656
  • [8] Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
    Salmon-Ceron, Dominique
    Durier, Christine
    Desaint, Corinne
    Cuzin, Lise
    Surenaud, Mathieu
    Ben Hamouda, Nadine
    Lelievre, Jean-Daniel
    Bonnet, Benedicte
    Pialoux, Gilles
    Poizot-Martin, Isabelle
    Aboulker, Jean-Pierre
    Levy, Yves
    Launay, Odile
    AIDS, 2010, 24 (14) : 2211 - 2223
  • [9] Entecavir treatment combined with DNA vaccine and recombinant fowlpox virus "prime-boost" vaccination for chronic hepatitis B virus infection
    Feng, Feng
    Teoh, Chee Quin
    Boyle, David
    Jilbert, Allison
    VACCINE, 2008,
  • [10] A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
    Churchyard, Gavin J.
    Morgan, Cecilia
    Adams, Elizabeth
    Hural, John
    Graham, Barney S.
    Moodie, Zoe
    Grove, Doug
    Gray, Glenda
    Bekker, Linda-Gail
    McElrath, M. Juliana
    Tomaras, Georgia D.
    Goepfert, Paul
    Kalams, Spyros
    Baden, Lindsey R.
    Lally, Michelle
    Dolin, Raphael
    Blattner, William
    Kalichman, Artur
    Figueroa, J. Peter
    Pape, Jean
    Schechter, Mauro
    Defawe, Olivier
    De Rosa, Stephen C.
    Montefiori, David C.
    Nabel, Gary J.
    Corey, Lawrence
    Keefer, Michael C.
    PLOS ONE, 2011, 6 (08):
12345